2月6日，针对近日部分媒体关于精神专科医院涉嫌违规问题的报道中，将襄阳恒泰康医院有限公司（下 称"襄阳恒泰康医院"）与爱尔眼科及其实际控制人陈邦直接关联的情况，爱尔眼科紧急回应，并对相关 股权关系及企业边界作出说明。 爱尔眼科方面表示，相关报道中部分表述存在概念混用，可能引发公众误解。 据此前报道，湖北多家精神专科医院被曝可能存在虚构诊疗项目、套取医保资金等问题，涉嫌违规，涉 事医院包括襄阳融诚医院、襄阳宏安医院、襄阳恒泰康医院、宜昌夷陵康宁精神病医院等。 关于襄阳恒泰康医院的股权结构及层级问题，爱尔眼科方面回应称，襄阳恒泰康医院并非爱尔眼科所属 企业。该公司为爱尔眼科控股股东——爱尔医疗投资集团有限公司（下称"爱尔医疗投资集团"）与其他 投资方合资设立的四级子公司，不属于爱尔眼科上市公司合并报表范围。作为投资人之一，爱尔医疗投 资集团及陈邦并不直接参与襄阳恒泰康医院的经营管理。 目前，作为股东方，爱尔医疗投资集团紧急督促襄阳恒泰康医院实际经营方、管理层全面核查相关情 况，并全面配合相关调查。 知情人士向上海证券报记者透露，爱尔医疗投资集团为持股平台，核心以投资爱尔眼科为主，聚焦眼科 诊疗领域。"这些年来，伴 ...

Core Viewpoint - The abrupt termination of the partnership between Novo Nordisk and Hims & Hers highlights the survival crisis faced by global weight loss drug giants amid the challenges posed by generic drugs and setbacks in innovative drug development [1][8]. Group 1: Partnership Breakdown - The collaboration between Novo Nordisk and Hims & Hers began on April 29, 2025, aiming to provide the authentic weight loss drug Wegovy through Hims & Hers' platform [2]. - The initial expectation was for Hims & Hers to guide patients from unregulated compounded drugs to the legitimate product, while Novo Nordisk sought to expand its digital channels [2][3]. - The partnership unraveled due to Hims & Hers' continued sale of compounded semaglutide, which violated compliance standards set by Novo Nordisk [2][3]. Group 2: Market Impact - Following the partnership's collapse, Hims & Hers' stock plummeted nearly 30%, resulting in a market value loss of approximately $5 billion, while Novo Nordisk's stock fell over 9%, erasing $9 billion in market capitalization [1]. - The incident reflects a broader crisis in the GLP-1 weight loss drug market, with Novo Nordisk facing intense competition from Eli Lilly's tirzepatide, which has outperformed semaglutide in weight loss efficacy [4][8]. Group 3: Regulatory and Compliance Issues - Novo Nordisk accused Hims & Hers of large-scale compounding and deceptive marketing practices that jeopardized patient safety, particularly concerning the use of "illegal foreign active pharmaceutical ingredients" [1][4]. - The FDA's resolution of the Wegovy shortage has significantly reduced the legal space for compounded drugs, leading to a survival crisis for compounding companies [5][8]. Group 4: Novo Nordisk's Strategic Response - In response to its challenges, Novo Nordisk is investing heavily in the development of new generation drugs, including a $2.2 billion prepayment to Septerna for oral weight loss drug development [7]. - The company is also building a digital healthcare ecosystem, having formed strategic partnerships with companies like Ping An Health to create a comprehensive obesity management system [7][8]. Group 5: Industry Dynamics - The global weight loss drug market is projected to exceed $50 billion in 2024, with the U.S. accounting for 80% of this market, indicating a highly lucrative yet competitive landscape [8]. - The rapid changes in the market, driven by both innovative competitors and generic drug proliferation, are forcing traditional pharmaceutical giants like Novo Nordisk to rethink their strategies in the face of compliance and channel challenges [8][9].